Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis

被引：4

作者：

Mastrantoni, Luca ^{[1
,3
]}

Beccia, Viria ^{[1
]}

Caira, Giulia ^{[1
]}

Trovato, Giovanni ^{[1
]}

Calegari, Maria Alessandra ^{[2
]}

Basso, Michele ^{[2
]}

Salvatore, Lisa ^{[1
,2
]}

Pozzo, Carmelo ^{[2
]}

Tortora, Giampaolo ^{[1
,2
]}

Bria, Emilio ^{[1
,2
]}

Orlandi, Armando ^{[1
]}

机构：

[1] Univ Cattolica Sacro Cuore, Med Oncol, Rome, Italy

[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Comprehens Canc Ctr, Rome, Italy

[3] Univ Cattolica Sacro Cuore, Med Oncol Dept, Via Pineta Sacchetti 217, I-00168 Rome, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 191卷

关键词：

Maintenance therapy; Anti-EGFR; Cetuximab; Panitumumab; Meta-analysis; FOLFIRI PLUS BEVACIZUMAB; EARLY TUMOR SHRINKAGE; 1ST-LINE TREATMENT; OPEN-LABEL; RAS; CETUXIMAB; CHEMOTHERAPY; INTERMITTENT; MULTICENTER; PANITUMUMAB;

D O I：

10.1016/j.critrevonc.2023.104106

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In RAS wild type (wt) metastatic colorectal cancer (mCRC) maintenance therapy after induction with fluoropyrimidine (FP)-based cytotoxic therapy (CT) plus anti-EGFR agents is controversial.Methods: Phase II-III randomized trials were included. Maintenance strategies considered were: observation, antiEGFR or FP monotherapy, FP + anti-EGFR, doublet CT + anti-EGFR.Results: Maintenance with FP + anti-EGFR (HR 0.56, 95% CrI 0.36-0.89) showed the greatest PFS benefit compared to observation, ranking first on SUCRA analysis (96.4%). Considering OS, doublet CT+ anti-EGFR, FP + anti-EGFR and anti-EGFR monotherapy yielded similar results. For PFS, FP + anti-EGFR confirmed to be valuable in BRAF wt patients and left sided tumors. In left sided tumors, the OS benefit of adding CT was limited. FP plus anti-EGFR showed a favourable safety profile compared to doublet CT + anti-EGFR. Conclusions: FP + anti-EGFR can be considered a valuable maintenance option in RAS wt mCRC. EGFR monotherapy can be considered, especially in left-sided tumors.

引用

页数：8

共 35 条

[1]

[Anonymous], 2022, Ann Oncol, V33, pS808, DOI [10.1016/annonc/annonc1089, DOI 10.1016/ANNONC/ANNONC1089]

[2] First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study [J].

Aranda, E. ;

Garcia-Alfonso, P. ;

Benavides, M. ;

Sanchez Ruiz, A. ;

Guillen-Ponce, C. ;

Safont, M. J. ;

Alcaide, J. ;

Gomez, A. ;

Lopez, R. ;

Manzano, J. L. ;

Mendez Urena, M. ;

Sastre, J. ;

Rivera, F. ;

Gravalos, C. ;

Garcia, T. ;

Martin-Valades, J. I. ;

Falco, E. ;

Navalon, M. ;

Gonzalez Flores, E. ;

Garcia Tapiador, A. Ma ;

Lopez Munoz, A. Ma ;

Barrajon, E. ;

Reboredo, M. ;

Garcia Teijido, P. ;

Viudez, A. ;

Cardenas, N. ;

Diaz-Rubio, E. .

EUROPEAN JOURNAL OF CANCER, 2018, 101 :263-272

[3] Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials [J].

Arnold, D. ;

Lueza, B. ;

Douillard, J. -Y. ;

Peeters, M. ;

Lenz, H. -J. ;

Venook, A. ;

Heinemann, V. ;

Van Cutsem, E. ;

Pignon, J. -P. ;

Tabernero, J. ;

Cervantes, A. ;

Ciardiello, F. .

ANNALS OF ONCOLOGY, 2017, 28 (08) :1713-1729

[4] Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study. [J].

Boige, Valerie ;

Francois, Eric ;

Ben Abdelghani, Meher ;

Phelip, Jean Marc ;

Le Brun-Ly, Valerie ;

Mineur, Laurent ;

Galais, Marie Pierre ;

Villing, Anne-Laure ;

Hautefeuille, Vincent ;

Miglianico, Laurent ;

De La Fouchardiere, Christelle ;

Genet, Dominique ;

Levasseur, Nadia ;

Levache, Charles-Briac ;

Lachaux, Nicolas ;

Gourgou, Sophie ;

Castan, Florence ;

Bouche, Olivier .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

[5] GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework [J].

Brignardello-Petersen, Romina ;

Florez, Ivan D. ;

Izcovich, Ariel ;

Santesso, Nancy ;

Hazlewood, Glen ;

Alhazanni, Waleed ;

Yepes-Nunez, Juan Jose ;

Tomlinson, George ;

Schunemann, Holger J. ;

Guyatt, Gordon H. .

BMJ-BRITISH MEDICAL JOURNAL, 2020, 371

[6] Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [J].

Cervantes, A. ;

Adam, R. ;

Rosello, S. ;

Arnold, D. ;

Normanno, N. ;

Taieb, J. ;

Seligmann, J. ;

De Baere, T. ;

Osterlund, P. ;

Yoshino, T. ;

Martinelli, E. .

ANNALS OF ONCOLOGY, 2023, 34 (01) :10-32

[7] Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial [J].

Cremolini, Chiara ;

Antoniotti, Carlotta ;

Rossini, Daniele ;

Lonardi, Sara ;

Loupakis, Fotios ;

Pietrantonio, Filippo ;

Bordonaro, Roberto ;

Latiano, Tiziana Pia ;

Tamburini, Emiliano ;

Santini, Daniele ;

Passardi, Alessandro ;

Marmorino, Federica ;

Grande, Roberta ;

Aprile, Giuseppe ;

Zaniboni, Alberto ;

Murgioni, Sabina ;

Granetto, Cristina ;

Buonadonna, Angela ;

Moretto, Roberto ;

Corallo, Salvatore ;

Cordio, Stefano ;

Antonuzzo, Lorenzo ;

Tomasello, Gianluca ;

Masi, Gianluca ;

Ronzoni, Monica ;

Di Donato, Samantha ;

Carlomagno, Chiara ;

Clavarezza, Matteo ;

Ritorto, Giuliana ;

Mambrini, Andrea ;

Roselli, Mario ;

Cupini, Samanta ;

Mammoliti, Serafina ;

Fenocchio, Elisabetta ;

Corgna, Enrichetta ;

Zagonel, Vittorina ;

Fontanini, Gabriella ;

Ugolini, Clara ;

Boni, Luca ;

Falcone, Alfredo .

LANCET ONCOLOGY, 2020, 21 (04) :497-507

[8] Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer A Randomized Phase 2 Clinical Trial [J].

Cremolini, Chiara ;

Antoniotti, Carlotta ;

Lonardi, Sara ;

Aprile, Giuseppe ;

Bergamo, Francesca ;

Masi, Gianluca ;

Grande, Roberta ;

Tonini, Giuseppe ;

Mescoli, Claudia ;

Cardellino, Giovanni Gerardo ;

Coltelli, Luigi ;

Salvatore, Lisa ;

Corsi, Domenico Cristiano ;

Lupi, Cristiana ;

Gemma, Donatello ;

Ronzoni, Monica ;

Dell'Aquila, Emanuela ;

Marmorino, Federica ;

Di Fabio, Francesca ;

Mancini, Maria Laura ;

Marcucci, Lorenzo ;

Fontanini, Gabriella ;

Zagonel, Vittorina ;

Boni, Luca ;

Falcone, Alfredo .

JAMA ONCOLOGY, 2018, 4 (04) :529-536

[9] Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer [J].

Douillard, J. Y. ;

Siena, S. ;

Cassidy, J. ;

Tabernero, J. ;

Burkes, R. ;

Barugel, M. ;

Humblet, Y. ;

Bodoky, G. ;

Cunningham, D. ;

Jassem, J. ;

Rivera, F. ;

Kocakova, I. ;

Ruff, P. ;

Blasinska-Morawiec, M. ;

Smakal, M. ;

Canon, J. L. ;

Rother, M. ;

Oliner, K. S. ;

Tian, Y. ;

Xu, F. ;

Sidhu, R. .

ANNALS OF ONCOLOGY, 2014, 25 (07) :1346-1355

[10] Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer [J].

Douillard, Jean-Yves ;

Siena, Salvatore ;

Peeters, Marc ;

Koukakis, Reija ;

Terwey, Jan-Henrik ;

Tabernero, Josep .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (10) :1231-1242

← 1 2 3 4 →